# 46662-2020 - Notifika minn qabel tal-għoti diretta

See the notice on TED website

**Ir-Renju Unit-Bristol: Servizzi patoloġiċi**
**OJ S 21/2020 30/01/2020**
**Avviż għal trasparenza ex ante volontarja**
**Servizzi**

**Il-bażi ġuridika:**
Direttiva 2014/24/UE

## Taqsima I: Awtorità/entità kontraenti

### I.1. Isem u indirizzi

Isem uffiċjali: North Bristol NHS Trust
Indirizz postali: Southmead Road, Bristol
Belt: Bristol
Kodiċi NUTS: UKK11 Bristol, City of
Kodiċi postali: BS10 5NB
Pajjiż: Ir-Renju Unit
Persuna ta' kuntatt: Martin Strawson
Posta elettronika: martin.strawson@UHBristol.nhs.uk
Telefown: +44 1173420815
**Indirizz(i) tal-Internet**:
Indirizz ewlieni: https://www.nbt.nhs.uk/

### I.4. Tip ta' awtorità kontraenti

Tip ieħor: NHS trust

### I.5. Attività ewlenija

Saħħa

## Taqsima II: L-għan

### II.1. L-għan tal-ksib

### II.1.1. Titlu

Procurement of a Large Throughput DNA Sequencer
Numru ta' referenza: BWPCCL001501

### II.1.2. Kodiċi ewlieni CPV

85111800 Servizzi patoloġiċi

### II.1.3. It-tip ta' kuntratt

Servizzi

### II.1.4. Deskrizzjoni qasira

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

**II.1.6. Informazzjoni dwar il-lottijiet**

Dan il-kuntratt huwa maqsum f'lottijiet: Ie

**II.1.7. Valur totali tal-ksib**

Valur mingħajr VAT: 779 625,00 GBP

**II.2. Deskrizzjoni**

**II.2.2. Kodiċi(jiet) addizzjonali tal-VKK**

85111000 Servizzi ta' l-isptar

**II.2.3. Il-post tat-twettiq**

Kodiċi NUTS: UKK11 Bristol, City of

**II.2.4. Deskrizzjoni tal-akkwist**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.
North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.
NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.
To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.
The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.
Procurement to comprise:
Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.
Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

**II.2.5. Kriterji tal-għoti**

Il-kriterju tal-kwalità - L-Isem: Quality / Peżar: 90
Prezz - Peżar: 10

**II.2.11.**

**Informazzjoni dwar l-għażliet**
Għażliet: le

**II.2.13. Informazzjoni dwar Fondi tal-Unjoni Ewropea**
L-akkwist huwa marbut ma' proġett u/jew programm iffinanzjat mill-fondi tal-Unjoni Ewropea: le

**II.2.14. Informazzjoni addizzjonali**

## Taqsima IV: Proċedura

### IV.1. Deskrizzjoni

**IV.1.1. Tip ta' proċedura**
Għoti ta' kuntratt mingħajr pubblikazzjoni minn qabel ta' sejħa għall-kompetizzjoni f'Il-Ġurnal Uffiċjali tal-Unjoni Ewropea fil-każijiet elenkati hawn taħt

- L-akkwist ma jaqax fl-ambitu tal-applikazzjoni tad-direttiva

Spjegazzjoni:
North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.
North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.
NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.
To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.
The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.
Procurement to comprise:
Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.
Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

**IV.1.3. Informazzjoni dwar ftehim qafas**

**IV.1.8. Informazzjoni dwar il-Ftehim dwar l-Akkwisti Pubbliċi (GPA)**
L-akkwist huwa kopert mill-GPA: le

### IV.2. Informazzjoni amministrattiva

## Taqsima V: Għoti ta' kuntratt/konċessjoni

**Titlu:**
Procurement of Large High Throughput DNA Sequencer

### V.2. Għoti ta' kuntratt/konċessjoni

### V.2.1. Data tad-deċiżjoni dwar l-għoti tal-kuntratt
28/01/2020

### V.2.2. Informazzjoni dwar sejħiet għall-offerti
Il-kuntratt ingħata lil grupp ta' operaturi ekonomiċi: Ie

### V.2.3. L-isem u l-indirizz tal-kuntrattur/konċessjonarju
Isem uffiċjali: Illumina Cambridge Ltd
Indirizz postali: Chesterford Research Park, Little Chesterford
Belt: Saffron Walden
Kodiċi NUTS: UKI London
Kodiċi postali: CB10 1XL
Pajjiż: Ir-Renju Unit
Il-kuntrattur/konċessjonarju se jkun SME: iva

### V.2.4. Informazzjoni dwar il-valur tal-kuntratt/lott/konċessjoni
Valur totali tal-kuntratt/lott/konċessjoni: 779 625,00 GBP

### V.2.5. Informazzjoni dwar is-sottokuntrattar

## Taqsima VI: Informazzjoni kumplimentari

### VI.3. Informazzjoni addizzjonali

### VI.4. Proċeduri ta' analiżi mill-ġdid

### VI.4.1. Korp responsabbli għall-proċeduri ta' analiżi mill-ġdid
Isem uffiċjali: Bristol and Weston Purchasing Consortium
Indirizz postali: Level 3, Whitefriars, Lewins Mead
Belt: Bristol
Kodiċi postali: BS1 2NT
Pajjiż: Ir-Renju Unit
Posta elettronika: martin.strawson@UHBristol.nhs.uk

### VI.4.2. Korp responsabbli għall-proċeduri ta’ medjazzjoni
Isem uffiċjali: Bristol and Weston Purchasing Consortium
Indirizz postali: Level 3, Whitefriars, Lewins Mead
Belt: Bristol
Kodiċi postali: BS1 2NT
Pajjiż: Ir-Renju Unit

### VI.4.4. Servizz minn fejn tista’ tinkiseb informazzjoni dwar il-proċedura ta' analiżi mill-ġdid
Isem uffiċjali: Bristol and Weston Purchasing Consortium
Indirizz postali: Level 3, Whitefriars, Lewins Mead
Belt: Bristol
Kodiċi postali: BS1 2NT

Pajjiż: Ir-Renju Unit

**VI.5. Data ta' meta ntbagħat dan l-avviż**

28/01/2020